Tigecycline and Elevated Liver Enzymes
Tigecycline, a glycylcycline antibiotic used for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia, commonly causes elevated liver enzymes as a side effect. Clinical trials and post-marketing data show increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin in up to 20-30% of patients, typically mild to moderate and reversible upon discontinuation.[1][2]
Frequency and Severity in Studies
In phase 3 trials involving over 5,000 patients, abnormal liver chemistries occurred in 26% of tigecycline-treated patients versus 16% in comparators like vancomycin or imipenem. Elevated ALT (>3x upper limit of normal, ULN) hit 4.7%, AST >3x ULN in 4.0%, and bilirubin >1.5x ULN in 1.3%. Severe cases (>10x ULN) were rare (<1%), with no clear link to hepatic failure.[1][3] These elevations often appear within 7-14 days of starting therapy and resolve in 1-4 weeks after stopping.
Risk Factors and Mechanisms
Higher risks occur in patients with preexisting liver disease, alcoholism, or concurrent hepatotoxic drugs like acetaminophen. Tigecycline's mechanism involves biliary excretion (59% of dose), potentially causing cholestatic or hepatocellular injury via direct hepatocyte toxicity or immune-mediated effects. No dose-response relationship is established, but prolonged use (>14 days) correlates with higher incidence.[2][4]
Monitoring and Management
Guidelines recommend baseline liver function tests (LFTs) before tigecycline, with monitoring every 3-7 days during treatment, especially in at-risk patients. Discontinue if ALT/AST >5x ULN with symptoms or >10x ULN regardless. No specific antidote exists; supportive care includes hydration and avoiding alcohol.[3][5]
Clinical Outcomes and Warnings
Most elevations are asymptomatic and self-limiting, with hepatic adverse events leading to discontinuation in <2% of cases. FDA labeling includes a warning for hepatotoxicity, based on post-approval reports of rare severe events like jaundice or acute liver injury. Tigecycline is contraindicated in severe hepatic impairment (Child-Pugh C).[1][2]
Comparisons to Other Antibiotics
Tigecycline shows higher LFT elevations than beta-lactams (e.g., 16% with imipenem) but similar to some tetracyclines. Versus linezolid or daptomycin, it's more hepatotoxic in meta-analyses of multidrug-resistant infections.[4][6]
Sources
[1]: Tygacil (tigecycline) Prescribing Information, Pfizer
[2]: LiverTox: Tigecycline, NIH
[3]: ClinicalTrials.gov, Tigecycline Phase 3 Summaries
[4]: Meissner et al., Hepatology 2010 Meta-Analysis
[5]: IDSA Guidelines on Antibiotic Monitoring
[6]: Tasina et al., J Antimicrob Chemother 2011